Clark S J, Creighton S, Horner M, Smith H M, Portmann B, Taylor C, Cramp M E
Department of Liver Studies, King's College Hospital, Denmark Hill, London, UK.
Int J STD AIDS. 2006 Jan;17(1):67-9. doi: 10.1258/095646206775220612.
The effect of HIV-related immunosuppression and antiretroviral therapy on the reactivation of latent hepatitis B virus (HBV) infection is unclear. We report four patients with advanced HIV-related immunosuppression and abnormal liver function tests who had evidence of HBV reactivation. Reclearance of hepatitis B occurred in two cases with HIV treatment regimens not containing lamivudine, suggesting that improved immune function may be responsible. In three cases, HBV reactivation was recognized during investigation for abnormal liver function initially attributed to drug toxicity. The possibility of HBV reactivation must be considered in the differential diagnosis of abnormal liver function in cases with advanced HIV.
人类免疫缺陷病毒（HIV）相关免疫抑制及抗逆转录病毒疗法对潜伏性乙型肝炎病毒（HBV）感染再激活的影响尚不清楚。我们报告了4例HIV相关严重免疫抑制且肝功能检查异常的患者，这些患者有HBV再激活的证据。在2例使用不含拉米夫定的HIV治疗方案的患者中，乙肝病毒清除，这表明免疫功能改善可能起了作用。在3例患者中，HBV再激活是在最初归因于药物毒性的肝功能异常调查期间被发现的。在晚期HIV患者肝功能异常的鉴别诊断中，必须考虑HBV再激活的可能性。
